Calidi Biotherapeutics Inc SEC Filings

Calidi Biotherapeutics insider grant: Chief Executive Officer Eric E. Poma was granted 10,000 incentive stock options under the issuer's 2023 Equity Incentive Plan on 09/03/2025 at an exercise price of $1.58, equal to the closing price that day. The options are exercisable beginning on the grant date and expire on 09/03/2035. Vesting is 25% after one year and the remaining 75% vests in 1/36th monthly installments thereafter, conditioned on continued service. The grant was made pursuant to Rule 16b-3 exemption.

Calidi Biotherapeutics insider grant: On 09/03/2025 the company's Chief Scientific Officer, Antonio Fernandez Santidrian, received a grant of 35,000 incentive stock options under the Issuer's 2023 Equity Incentive Plan.

The options have an exercise price of $1.58, which equals the common stock closing price on the grant date. Twenty-five percent of the options vest after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. The options are exercisable beginning 09/03/2025 and expire 09/03/2035. The grant was made pursuant to Rule 16b-3.

Calidi Biotherapeutics, Inc. (CLDI) reported that Andrew C. Jackson, the companys Chief Financial Officer, was granted 30,000 incentive stock options on 09/03/2025 under the 2023 Equity Incentive Plan. The options have an exercise price of $1.58, which the filing states equals the closing price on the grant date. Twenty-five percent of the options vest after one year, with the remaining 75% vesting in equal monthly installments over the following three years. The options are exercisable beginning 09/03/2025 and expire on 09/03/2035. The grant was reported as exempt under Rule 16b-3.

Lincoln Alternative Strategies LLC reports beneficial ownership of 730,000 shares of Calidi Biotherapeutics, representing 14.46% of the outstanding common stock based on 5,049,210 shares. The filer, organized in Delaware and located in Miami Beach, discloses sole voting and dispositive power over the reported shares and states the holdings were not acquired to change or influence control of the issuer. The filing identifies the class as common stock (par value $0.0001) and supplies the issuer's principal executive office in San Diego. No shared voting or dispositive power is reported.

Calidi Biotherapeutics (CLDI) Form 3 reports that Lincoln Alternative Strategies LLC filed an initial beneficial ownership statement following an 08/20/2025 event. The filing shows 730,000 shares of Common Stock held in direct ownership. No derivative securities are reported. The form was signed by Stephen Temes on 08/27/2025 and indicates the filer is a director of the issuer and the Form was filed by one reporting person.

Calidi Biotherapeutics, Inc. (CLDI) reporting person James A. Schoeneck acquired securities in a public offering that closed on 08/21/2025. The Form 4 shows acquisition of 75,000 common shares and 75,000 warrants exercisable into common stock through 08/21/2030, with a combined purchase price of $2.00 per share and accompanying warrant. Following the transactions, Mr. Schoeneck directly beneficially owns 76,134 common shares and indirectly holds 8,033 shares through the James & Cynthia Schoeneck Family Trust, where he is a trustee.

The filing was signed by an attorney-in-fact on 08/25/2025 and references a previously filed Power of Attorney as Exhibit 24. The reporting person disclaims beneficial ownership of the trust shares except to the extent of pecuniary interest.

Eric E. Poma, who serves as Chief Executive Officer and a director of Calidi Biotherapeutics, Inc. (CLDI), acquired 25,000 shares of common stock and 25,000 warrants in a public offering that closed on 08/21/2025. Each share was purchased together with a warrant at a combined purchase price of $2.00 per share and accompanying warrant. Following the reported transactions, the reporting person beneficially owns 25,000 shares directly. The Form 4 was executed by an attorney-in-fact and filed with a signature dated 08/25/2025.

Reporting person: Scott Leftwich, a director of Calidi Biotherapeutics, Inc. (CLDI), purchased securities in the issuer's public offering that closed on 08/21/2025. He acquired 125,000 common shares with accompanying 125,000 warrants (exercise price $2.00, exercisable 08/21/2025, expiring 08/21/2030) for an aggregate per-share-and-warrant price of $2.00. Following the transaction, the reporting person directly beneficially owned 130,650 common shares and indirectly beneficially owned an additional 14,672 shares through SECBL, LLC and 1,309 shares through WEBCL, LLC, of which he is the managing member. The Form 4 was signed by an attorney-in-fact on 08/25/2025.